GLUCAGON LIKE PEPTIDE 1 ANALOGS MARKET ANALYSIS

Glucagon Like Peptide 1 Analogs MarketSize and Trends

High prevalence of diabetes in the U.S. and Asia-Pacific is expected to drive the growth of Glucagon-like peptide-1 analogs market

According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2017, around 425 million patients are suffering from diabetes worldwide. According to World Health Organization (WHO) report 2017, diabetes is one of top three cause of death among the non-communicable diseases. China (114.4 million), India (72.9 million) and U.S. (30.2 million) are top three economies having high prevalence of diabetes. Such high number of prevalence would offers an immense growth opportunity to the GLP-1 analogs market. This is also from the fact that approximately 212.4 million people worldwide are with undiagnosed diabetes. According to the International Diabetes Federation (IDF), the U.S. has highest prevalence of diabetes (13% of population), which is expected to drive the growth of glucagon-like peptide-1 analogs market, owing to cost effectiveness and high penetration of these product in market. GLP-1 analogs not only act in type-2 diabetes but also in type 1 diabetes with almost nil hypoglycemic effect, according to the study published in the Journal of American Health and Drug Benefit. According to study published in journal Obesity Review (2017), GLP-1 analogs aid in weight reduction of diabetic as well as non-diabetic obese patient. GLP-1 analog liraglutide is already approved in treating obese and overweight patient, which is expected to fuel the growth of the GLP-1 analogs market.

Increasing awareness amongst physicians regarding benefits of GLP-1 analogs over conventional anti-diabetic medication is propelling the growth of the market.

Glucagon-Like Peptide-1 Analogs Market Taxonomy:

On the basis of drug:

• Exenatide
• Liraglutide
• Lixisenatide
• Dulaglutide
• Semaglutide
• Albiglutide

On the basis of distribution channel:

• Retail Pharmacy
• Hospital pharmacy